Treatments and clinical courses in patients with TAK and GCA. Two patients with GCA with short-term followup (< 6 mos) were excluded when assessing clinical courses. The proportions of the 4 categories were different between TAK and GCA (p = 0.02), thus standardized residuals were calculated. Values are n (%) unless otherwise specified.
| Variables | TAK, n = 23 | GCA, n = 22 | Standardized Residual |
|---|---|---|---|
| Median followup period, mos (range) | 78.2 (9.9–361.7) | 42.7 (0–125.3) | |
| Glucocorticoids | 18 (78) | 21 (95) | |
| Treatments | |||
| Median maximum dose, mg/day | 40 | 40 | |
| ≥ 1 immunosuppressants | 18 (78) | 18 (82) | |
| ≥ 2 immunosuppressants | 12 (52) | 10 (45) | |
| Biologics | 9 (39) | 1 (5) | |
| Vascular intervention | 8 (35) | 2 (9) | |
| No. deaths | 1 (4) | 2 (9) | |
| Clinical courses | |||
| No relapse | 5 (22) | 12 (60) | 2.6* |
| Relapsing | 8 (35) | 6 (30) | 0.3 |
| Refractory | 5 (22) | 2 (10) | 1.0 |
| Burn-out | 5 (22) | 0 (0) | 2.2* |
↵* p < 0.05. TAK: Takayasu arteritis; GCA: giant cell arteritis.